Understanding the Evidence on Tysabri and PML Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of General Health and Science Information

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that this rare brain infection is a known complication of natalizumab therapy. This page reviews what current published studies and FDA reports say about PML risk, including key factors like JC virus antibody status and duration of treatment.

Bridge: From General Awareness to Specific Risk

Building on the legacy of general health information, it is crucial to transition to a detailed understanding of Tysabri's specific risks. Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus. PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration has assigned a boxed warning to Tysabri, emphasizing that the drug increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, withholding dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

Clinical presentation of PML is variable but typically includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain imaging, typically MRI showing multifocal white matter lesions, and detection of JC virus DNA in cerebrospinal fluid. The condition is often fatal, and survivors may experience permanent disability. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing reactivation of latent JC virus in the brain. The virus then infects oligodendrocytes, leading to demyelination and the characteristic lesions of PML.

Risk Factors and Regulatory Context

Three key risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal and Settlement Considerations

The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning clearly states that Tysabri increases the risk of PML and that risk factors include anti-JCV antibodies, duration of therapy, and prior immunosuppressant use. However, some patients and their families have argued that these warnings were not sufficiently communicated or that the risks were downplayed, particularly in the context of long-term treatment. Settlement-related considerations for affected patients often involve evaluating whether the treating physician adequately monitored for PML symptoms and whether the patient was informed of the risk. The timeline between exposure and documented harm is critical: PML can develop after months to years of Tysabri use, with risk increasing after two years of treatment. In clinical trials, the two MS patients developed PML after a median of 120 weeks, while the Crohn's disease patient developed it after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period complicates attribution of harm, as other factors such as prior immunosuppressant use may also contribute. For patients diagnosed with PML after Tysabri exposure, legal claims may focus on failure to warn, inadequate monitoring, or product liability. Settlements in New Jersey, where many pharmaceutical cases are litigated, often consider the severity of disability, medical expenses, and loss of quality of life. The boxed warning and restricted distribution program demonstrate that the manufacturer recognized the risk, but plaintiffs may argue that the warnings were insufficient to prevent harm. The presence of anti-JCV antibodies and duration of therapy are central to risk assessment, and failure to test for antibodies or to discontinue therapy after two years could be seen as deviations from standard of care.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a monoclonal antibody used for relapsing forms of multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus, due to its immunosuppressive effects that reduce immune surveillance in the brain (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the key risk factors for developing PML while on Tysabri?

The three main risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed and what is its prognosis?

Diagnosis involves brain MRI showing multifocal white matter lesions and detection of JC virus DNA in cerebrospinal fluid. PML is often fatal, and survivors may experience permanent disability such as weakness, cognitive decline, and coordination problems.

What legal options are available for patients who developed PML after Tysabri use?

Patients may pursue claims for failure to warn, inadequate monitoring, or product liability. Settlements in New Jersey consider the severity of disability, medical expenses, and loss of quality of life. The adequacy of warnings and adherence to monitoring protocols are key factors.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.